Dabur Pharma, a leading company for cancer research and oncology drugs, was renamed Fresenius Kabi Oncology after its acquisition by Fresenius Kabi, the leader in infusion therapy and clinical nutrition in Europe, Latin America, Asia Pacific as well as in the US, where it is a leading supplier of IV generic drugs.
The company markets its products to various part of world namely Bangladesh, Sri Lanka, Thailand, Philippines, Malaysia, Vietnam, Myanmar, Jordan, Russia, Ukraine, Georgia,
Dabur Pharma, a leading company for cancer research and oncology drugs, was renamed Fresenius Kabi Oncology after its acquisition by Fresenius Kabi, the leader in infusion therapy and clinical nutrition in Europe, Latin America, Asia Pacific as well as in the US, where it is a leading supplier of IV generic drugs.
The company markets its products to various part of world namely Bangladesh, Sri Lanka, Thailand, Philippines, Malaysia, Vietnam, Myanmar, Jordan, Russia, Ukraine, Georgia, Kazakhstan, Uzbekistan, Hungary, Kenya, Nigeria, Ghana, Zimbabwe, Brazil, Venezuela, Mexico, and many more.
The manufacturing facilities are located in Bordon (U.K.), Kalyani (India) and Baddi (India). These plants are approved by the regulatory bodies of countries like Brazil, Colombia, Malaysia, Turkey, Pakistan, Ukraine, Sudan, Belarus Hungary, Jordan, Zimbabwe, Yemen.
Products
APIs- It manufactures Active Pharmaceutical Ingredients (API) for anti cancer, drug intermediate, calcium regulator, muscle relaxant, Analgesic and many more.
Oncology- Under this it has created drugs like Intaxel, Nanoxel.
Other range of generic products offered by Fresenius Kabi Oncology includes, Taxane Analogues, Alkylating Agents, Anti-Metabolites, Cytostatic Antibiotics, Cytostatic hormone therapies.
